Abstract
An obese woman was treated with oral tedizolid 200 mg once daily for pseudoarthrosis 10 years after Roux-en-Y bypass surgery. Total plasma peak concentration was 2.12 mg/liter 3 h after intake, and area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) was 28.3 mg/liter · h. The AUC 0-24 /MIC ratio for unbound concentrations and for sensitive Staphylococcus and Streptococcus strains was ≥10.8, higher than the target ratio of 3. These results support the use of tedizolid without adjustment after bariatric surgery.
Author supplied keywords
Cite
CITATION STYLE
Grégoire, M., Libois, J. B., Waast, D., Gaborit, B., Dauty, M., Deslandes, G., … Couet, W. (2018). Pharmacokinetics of tedizolid in an obese patient after bariatric surgery. Antimicrobial Agents and Chemotherapy, 62(4). https://doi.org/10.1128/AAC.02432-17
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.